Clement Dumont
Overview
Explore the profile of Clement Dumont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
118
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gabriel P, Gauthier H, Xylinas E, Hermieu J, Desgrandchamps F, Hennequin C, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102312.
PMID: 40023937
Purpose: Emerging therapies including anti-PD-(L)1 immunotherapy have changed paradigms of treatment and improved oncological outcomes of advanced/metastatic urothelial carcinoma (mUC) patients. An emerging challenge in this setting is the management...
2.
Dumont C, Aregui A, Hauchecorne M, Lefevre M, Aussedat Q, Reignier P, et al.
World J Urol
. 2023 Aug;
41(10):2715-2722.
PMID: 37555987
Purpose: This study aimed at describing the feasibility and oncological outcomes of standard cisplatin-based neoadjuvant chemotherapy (C-NAC) for muscle-invasive bladder cancer (MIBC) in patients aged ≥ 75 and assess the...
3.
Reignier P, Gauthier H, Hennequin C, Aussedat Q, Xylinas E, Desgrandchamps F, et al.
World J Urol
. 2023 Jul;
41(11):3249-3255.
PMID: 37410102
Purpose: to assess the respective outcomes of patients with localized muscle-invasive bladder cancer (MIBC) treated by either radical cystectomy (RC) or trimodal treatment (TMT) depending on pathological response to previous...
4.
Plais H, Dumont C, Gauthier H, Culine S
Immunotherapy
. 2023 May;
15(10):729-735.
PMID: 37139988
The optimal duration of treatment for metastatic patients who achieve a complete response with immune checkpoint inhibitors is unknown. The outcome for six metastatic bladder cancer patients who received short...
5.
Parent P, Auclin E, Patrikidou A, Mezquita L, Martinez Chanza N, Dumont C, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831409
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical outcomes...
6.
Dumont C, Masson-Lecomte A, Desgrandchamps F, Culine S
Rev Prat
. 2022 Dec;
72(7):803-805.
PMID: 36511974
No abstract available.
7.
Helal C, Lambert T, Joly B, Dumont C, Gauthier H, Culine S
Case Rep Oncol
. 2022 Sep;
15(2):745-749.
PMID: 36157695
Heart metastases from urothelial carcinoma of the bladder have rarely been reported in the literature. We present a case complicated by symptomatic disseminated intravascular coagulation in a 67-year-old woman. A...
8.
Evrard D, Dumont C, Gatineau M, Delord J, Fayette J, Dreyer C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139669
Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and signals from the tumor microenvironment (TME). The PI3K-AKT-mTOR pathway is activated in 70% of head and neck...
9.
Sitbon M, Chou P, Bengaly S, Poirot B, Laloi-Michelin M, Deville L, et al.
Eur Thyroid J
. 2022 Sep;
11(6).
PMID: 36069795
The endocrine secretions of carcinomas can be life-threatening. Medullary thyroid carcinoma (MTC) is a rare cancer that is often associated with cortisol secretion, leading to paraneoplastic Cushing's syndrome. Mutations of...
10.
Lugand L, Mestrallet G, Laboureur R, Dumont C, Bouhidel F, Djouadou M, et al.
Front Oncol
. 2022 Aug;
12:898732.
PMID: 35965544
Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with...